Skip to main content

Drug Interactions between Carnexiv and Diltia XT

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Major

dilTIAZem carBAMazepine

Applies to: Diltia XT (diltiazem) and Carnexiv (carbamazepine)

ADJUST DOSE: Coadministration with diltiazem or verapamil may significantly increase the plasma concentrations of carbamazepine. The proposed mechanism is inhibition of carbamazepine metabolism via CYP450 3A4. There have been case reports of carbamazepine toxicity associated with the use of both calcium channel blockers (CCBs), which is consistent with their status as moderate CYP450 3A4 inhibitors. The onset is usually within 2 to 4 days after initiation of the CCB, and a reduction in carbamazepine dosage by 50% to 60% or discontinuation of the CCB is often required. A retrospective study found that 10 of 15 patients receiving carbamazepine with diltiazem or verapamil experienced signs and symptoms of toxicity, but not those receiving carbamazepine with nifedipine. Reduced carbamazepine levels and epileptic episodes have also been observed following withdrawal of CCB therapy. Conversely, carbamazepine may induce the first-pass metabolism and decrease the plasma concentrations of diltiazem and verapamil, although the magnitude of this interaction has not been studied.

MANAGEMENT: Caution is advised during concomitant use of carbamazepine with diltiazem or verapamil. Serum carbamazepine levels and pharmacologic response should be monitored more closely following the initiation or discontinuation of CCB therapy, and the carbamazepine dosage adjusted as necessary. Some clinicians recommend empirically reducing the carbamazepine dosage by 50% upon initiation of the CCB. Patients should be advised to contact their physician if they experience potential signs and symptoms of carbamazepine toxicity such as headache, nausea, vomiting, dizziness, confusion, slurred speech, nystagmus, visual disturbances, tremors, and ataxia. If carbamazepine is added to existing diltiazem or verapamil therapy, patients should be monitored for potentially reduced blood pressure and cardiac effects.

References

  1. Brodie MJ, MacPhee GJ "Carbamazepine neurotoxicity precipitated by diltiazem." Br Med J 292 (1986): 1170-1
  2. MacPhee GJ, McInnes GT, Thompson GG, Brodie MJ "Verapamil potentiates carbamazepine neurotoxicity: a clinically important inhibitory interaction." Lancet Mar (1986): 700-3
  3. Beattie B, Biller J, Mehlhaus B, Murray M "Verapamil-induced carbamazepine neurotoxicity." Eur Neurol 28 (1988): 104-5
  4. Price WA, DiMarzio LR "Verapamil-carbamazepine neurotoxicity." J Clin Psychiatry 49 (1988): 80
  5. Bahls FH, Ozuna J, Ritchie DE "Interactions between calcium channel blockers and the anticonvulsants carbamazepine and phenytoin." Neurology 41 (1991): 740-2
  6. Eimer M, Carter BL "Elevated serum carbamazepine concentrations following diltiazem initiation." Drug Intell Clin Pharm 21 (1987): 340-2
  7. Ahmad S "Diltiazem-carbamazepine interaction." Am Heart J 120 (1990): 1485-6
  8. Gadde K, Calabrese JR "Diltiazem effect on carbamazepine levels in manic depression." J Clin Psychopharmacol 10 (1990): 378-9
  9. Shaughnessy AF, Mosley MR "Elevated carbamazepine levels associated with diltiazem use." Neurology 42 (1992): 937-8
  10. MacPhee GJ, McInnes GT, Agnew E, Brodie MJ "Clinically relevant adverse interaction between verapamil and carbamazepine in epileptic patients." Proc BR Paedod Soc Dec (1985): p569-70
  11. Maoz E, Grossman E, Thaler M, Rosenthal T "Carbamazepine neurotoxic reaction after administration of diltiazem." Arch Intern Med 152 (1992): 2503-4
  12. Spina E, Pisani F, Perucca E "Clinically significant pharmacokinetic drug interactions with carbamazepine - an update." Clin Pharmacokinet 31 (1996): 198-214
  13. Patsalos PN, Perucca E "Clinically important drug interactions in epilepsy: interactions between antiepileptic drugs and other drugs." Lancet Neurol 2 (2003): 473-81
  14. Wijdicks EF, Arendt C, Bazzell MC "Postoperative ophthalmoplegia and ataxia due to carbamazepine toxicity facilitated by diltiazem." J Neuroophthalmol 24 (2004): 95
View all 14 references

Switch to consumer interaction data

Drug and food interactions

Moderate

dilTIAZem food

Applies to: Diltia XT (diltiazem)

MONITOR: Like many CNS-active agents, alcohol can exhibit hypotensive effects. Coadministration with antihypertensive agents including diltiazem may result in additive effects on blood pressure and orthostasis.

MONITOR: Grapefruit juice may increase the plasma concentrations of orally administered diltiazem in some patients. The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit. In a study of ten healthy male volunteers, administration of a single 120 mg oral dose of immediate-release diltiazem in combination with 250 mL of grapefruit juice increased the diltiazem peak plasma concentration (Cmax) and systemic exposure (AUC) by an average of 22% and 20%, respectively, compared to administration with water. The time to reach Cmax (Tmax) and the terminal half-life were not affected, and no statistically significant differences in blood pressure and heart rate were observed during administration with grapefruit juice relative to water. In a different study, repeated administration of 200 mL of grapefruit juice at 0, 2, 4, 8 and 12 hours had no significant effect on the Cmax or AUC of a single 120 mg oral dose of diltiazem, but increased its half-life from 4.1 to 5.1 hours. The ratios for the N-demethyl and deacetyl metabolites to diltiazem were also not affected by grapefruit juice. However, because pharmacokinetic interactions involving grapefruit juice are often subject to a high degree of interpatient variability, the extent to which a given patient may be affected is difficult to predict.

MANAGEMENT: Patients should be advised that alcohol may potentiate the hypotensive effects of diltiazem, especially during the initiation of therapy and following a dosage increase. Caution should be exercised when rising from a sitting or recumbent position, and patients should notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia. Patients who regularly consume grapefruit or grapefruit juice should be monitored for increased adverse effects of diltiazem such as such as headache, irregular heartbeat, edema, unexplained weight gain, and chest pain. Grapefruit and grapefruit juice should be avoided if an interaction is suspected.

References

  1. Bailey DG, Arnold JMO, Spence JD "Grapefruit juice and drugs - how significant is the interaction." Clin Pharmacokinet 26 (1994): 91-8
  2. Sigusch H, Henschel L, Kraul H, Merkel U, Hoffmann A "Lack of effect of grapefruit juice on diltiazem bioavailability in normal subjects." Pharmazie 49 (1994): 675-9
  3. Bailey DG, Malcolm J, Arnold O, Spence JD "Grapefruit juice-drug interactions." Br J Clin Pharmacol 46 (1998): 101-10
  4. Christensen H, Asberg A, Holmboe AB, Berg KJ "Coadministration of grapefruit juice increases systemic exposure of diltiazem in healthy volunteers." Eur J Clin Pharmacol 58 (2002): 515-520
  5. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
View all 5 references

Switch to consumer interaction data

Moderate

carBAMazepine food

Applies to: Carnexiv (carbamazepine)

GENERALLY AVOID: Alcohol may potentiate some of the pharmacologic effects of carbamazepine. Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.

In a small, randomized, crossover study, the administration of carbamazepine with grapefruit juice (compared to water) increased plasma drug concentrations by approximately 40%. The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruits.

MANAGEMENT: Patients receiving carbamazepine should be advised to avoid or limit consumption of alcohol. Given the drug's narrow therapeutic index, patients receiving carbamazepine therapy should preferably avoid the regular consumption of grapefruits and grapefruit juice to prevent any undue fluctuations in plasma drug levels. Patients should be advised to report signs of carbamazepine toxicity (nausea, visual disturbances, dizziness, or ataxia) to their physicians.

References

  1. "Product Information. Tegretol (carbamazepine)." Novartis Pharmaceuticals PROD (2002):
  2. Garg SK, Kumar N, Bhargava VK, Prabhakar SK "Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy." Clin Pharmacol Ther 64 (1998): 286-8
  3. Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77

Switch to consumer interaction data

Moderate

dilTIAZem food

Applies to: Diltia XT (diltiazem)

MONITOR: Calcium-containing products may decrease the effectiveness of calcium channel blockers by saturating calcium channels with calcium. Calcium chloride has been used to manage acute severe verapamil toxicity.

MANAGEMENT: Management consists of monitoring the effectiveness of calcium channel blocker therapy during coadministration with calcium products.

References

  1. Henry M, Kay MM, Viccellio P "Cardiogenic shock associated with calcium-channel and beta blockers: reversal with intravenous calcium chloride." Am J Emerg Med 3 (1985): 334-6
  2. Moller IW "Cardiac arrest following intravenous verapamil combined with halothane anaesthesia." Br J Anaesth 59 (1987): 522-6
  3. Oszko MA, Klutman NE "Use of calcium salts during cardiopulmonary resuscitation for reversing verapamil-associated hypotension." Clin Pharm 6 (1987): 448-9
  4. Schoen MD, Parker RB, Hoon TJ, et al. "Evaluation of the pharmacokinetics and electrocardiographic effects of intravenous verapamil with intravenous calcium chloride pretreatment in normal subjects." Am J Cardiol 67 (1991): 300-4
  5. O'Quinn SV, Wohns DH, Clarke S, Koch G, Patterson JH, Adams KF "Influence of calcium on the hemodynamic and anti-ischemic effects of nifedipine observed during treadmill exercise testing." Pharmacotherapy 10 (1990): 247
  6. Woie L, Storstein L "Successful treatment of suicidal verapamil poisoning with calcium gluconate." Eur Heart J 2 (1981): 239-42
  7. Morris DL, Goldschlager N "Calcium infusion for reversal of adverse effects of intravenous verapamil." JAMA 249 (1983): 3212-3
  8. Guadagnino V, Greengart A, Hollander G, Solar M, Shani J, Lichstein E "Treatment of severe left ventricular dysfunction with calcium chloride in patients receiving verapamil." J Clin Pharmacol 27 (1987): 407-9
  9. Luscher TF, Noll G, Sturmer T, Huser B, Wenk M "Calcium gluconate in severe verapamil intoxication." N Engl J Med 330 (1994): 718-20
  10. Bar-Or D, Gasiel Y "Calcium and calciferol antagonise effect of verapamil in atrial fibrillation." Br Med J (Clin Res Ed) 282 (1981): 1585-6
  11. Lipman J, Jardine I, Roos C, Dreosti L "Intravenous calcium chloride as an antidote to verapamil-induced hypotension." Intensive Care Med 8 (1982): 55-7
  12. McMillan R "Management of acute severe verapamil intoxication." J Emerg Med 6 (1988): 193-6
  13. Perkins CM "Serious verapamil poisoning: treatment with intravenous calcium gluconate." Br Med J 2 (1978): 1127
  14. Moroni F, Mannaioni PF, Dolara A, Ciaccheri M "Calcium gluconate and hypertonic sodium chloride in a case of massive verapamil poisoning." Clin Toxicol 17 (1980): 395-400
View all 14 references

Switch to consumer interaction data

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.


Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.